Barrier Therapeutics, Inc., a pharmaceutical company that develops and markets dermatology products, today announced that it has completed patient enrollment for its pivotal Phase 3 clinical study of Hyphanox(TM), a novel patented oral formulation of the antifungal agent itraconazole, for the treatment of toenail onychomycosis.
From: biz.yahoo.com
TM) for Onychomycosis
Posted by Ruslan Abuzant at 5:21 AM
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment